Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Graft-Versus-Host Disease (GvHD) and Steroid-Refractory GvHD after Allogeneic Hematopoietic Stem Cell Transplantation: A Large Real-World EBMT-Based Epidemiology and Treatment Pattern Study

Blood (2023) 142 (Supplement 1): 7016.

https://doi.org/10.1182/blood-2023-177866

Published: 2023

Journal Articles

TIM-3 Inhibitor Sabatolimab for Patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): Preliminary Findings from the Phase Ib/II Stimulus-AML2 Study

Robert Zeiser, Raynier Devillier, Maria Caterina Mico', David Valcarcel, Simon Call, Christian Niederwieser, Claire Nourry, Yunnan Xu, Thierry Medts, Nathalie Guichard, Hans D. Menssen, Nicola Polverelli

Blood (2023) 142 (Supplement 1): 59.

https://doi.org/10.1182/blood-2023-180876

Published: 2023

Journal Articles

Clinical Safety and Efficacy of Narsoplimab in Pediatric and Adult Patients with Transplant-Associated Thrombotic Microangiopathy: A Real-World Experience

Marta Castelli, Maria Caterina Mico', Anna Grassi, Alessandra Algarotti, Maria Chiara Finazzi, Benedetta Rambaldi, Cristian Meli, Giuliana Rizzuto, Chiara Pavoni, Francesca Vendemini, Marta Verna, Sonia Bonanomi, Adriana Balduzzi, Andrea Biondi, Alessandro Rambaldi, Giacomo Gotti

Blood (2023) 142 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2023-180917

Published: 2023

Journal Articles

Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Blood (2022) 140 (Supplement 1): 10622–10623.

https://doi.org/10.1182/blood-2022-162298

Published: 2022

Journal Articles

Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 7667–7669.

https://doi.org/10.1182/blood-2022-162472

Published: 2022

Journal Articles

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

Hannah Choe, MD, Nirav N. Shah, MD, Patrice Chevallier, MD PhD, Marie Thérèse Rubio, MD PhD, Mark A. Schroeder, MD, Nancy M. Hardy, MD, Patrick J. Stiff, MD, Carlos Solano, MD PhD, Ibrahim Yakoub-Agha, Jonathan A. Gutman, MD, Scott D. Rowley, MD, Maria Caterina Mico', MD, Elisabetta Terruzzi, MD, Rafael F. Duarte, MD PhD FRCP, Rodica Morariu-Zamfir, MD, Michael Arbushites, Kai Ding, PhD, Miguel-Angel Perales, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140747

Published: 2020

Journal Articles

Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation

Blood (2016) 128 (22): 1160.

https://doi.org/10.1182/blood.V128.22.1160.1160

Published: 2016

Journal Articles

A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease

Martino Introna, MD, Elisa Gotti, BA, Michela Bonzi, BA, Josee Golay, PhDBA, Alessandra Algarotti, MD, Caterina Micò, MD, Anna Grassi, MD, Cristina Boschini, Maria Luisa Ferrari, BSc, Irene Cavattoni, MD, Ettore Biagi, MD, Adriana Balduzzi, Sr., MD, Attilio Rovelli, MD, Paolo Perseghin, MD, Giuseppe Gaipa, PhD, Andrea Biondi, Alessandro Rambaldi, MD

Blood (2015) 126 (23): 3160.

https://doi.org/10.1182/blood.V126.23.3160.3160

Published: 2015

Journal Articles

Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Blood (2014) 124 (21): 727.

https://doi.org/10.1182/blood.V124.21.727.727

Published: 2014

Journal Articles

Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey

Marco Ruggeri, Francesco Rodeghiero, Alberto Tosetto, Giancarlo Castaman, Francesca Scognamiglio, Guido Finazzi, Federica Delaini, Caterina Micò, Alessandro M. Vannucchi, Elisabetta Antonioli, Valerio De Stefano, Tommaso Za, Luigi Gugliotta, Alessia Tieghi, Maria Gabriella Mazzucconi, Cristina Santoro, Tiziano Barbui

Blood (2008) 111 (2): 666–671.

https://doi.org/10.1182/blood-2007-07-102665

Published: 2008

Includes: Supplemental data

Journal Articles

Treosulfan - Fludarabine as Ablative Conditioning Regimen for Patients with High Risk Hematologic Malignancies.

Donatella Baronciani, MD, Alessandro Rambaldi, MD, Federica Pilo, MD, Caterina Mico, MD, Simona Deplano, MD, Cristina Depau, MD, Paolo Dessalvi, MD, Emanuele Angelucci, MD

Blood (2006) 108 (11): 5248.

https://doi.org/10.1182/blood.V108.11.5248.5248

Published: 2006

NARROW

Graft-Versus-Host Disease (GvHD) and Steroid-Refractory GvHD after Allogeneic Hematopoietic Stem Cell Transplantation: A Large Real-World EBMT-Based Epidemiology and Treatment Pattern Study

TIM-3 Inhibitor Sabatolimab for Patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): Preliminary Findings from the Phase Ib/II Stimulus-AML2 Study

Clinical Safety and Efficacy of Narsoplimab in Pediatric and Adult Patients with Transplant-Associated Thrombotic Microangiopathy: A Real-World Experience

Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation

A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease

Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey

Treosulfan - Fludarabine as Ablative Conditioning Regimen for Patients with High Risk Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only